187 related articles for article (PubMed ID: 21043806)
1. Integrated strategy for the production of therapeutic retroviral vectors.
Carrondo M; Panet A; Wirth D; Coroadinha AS; Cruz P; Falk H; Schucht R; Dupont F; Geny-Fiamma C; Merten OW; Hauser H
Hum Gene Ther; 2011 Mar; 22(3):370-9. PubMed ID: 21043806
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT).
Hum Gene Ther Clin Dev; 2014 Jun; 25(2):65-6. PubMed ID: 24933565
[No Abstract] [Full Text] [Related]
3. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
Schucht R; Coroadinha AS; Zanta-Boussif MA; Verhoeyen E; Carrondo MJ; Hauser H; Wirth D
Mol Ther; 2006 Aug; 14(2):285-92. PubMed ID: 16697259
[TBL] [Abstract][Full Text] [Related]
4. HEK293-based production platform for γ-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA.
Hennig K; Raasch L; Kolbe C; Weidner S; Leisegang M; Uckert W; Titeux M; Hovnanian A; Kuehlcke K; Loew R
Hum Gene Ther Clin Dev; 2014 Dec; 25(4):218-28. PubMed ID: 25381930
[TBL] [Abstract][Full Text] [Related]
5. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.
Goto M; Sawamura D; Ito K; Abe M; Nishie W; Sakai K; Shibaki A; Akiyama M; Shimizu H
J Invest Dermatol; 2006 Apr; 126(4):766-72. PubMed ID: 16439972
[TBL] [Abstract][Full Text] [Related]
6. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange.
Coroadinha AS; Schucht R; Gama-Norton L; Wirth D; Hauser H; Carrondo MJ
J Biotechnol; 2006 Jul; 124(2):457-68. PubMed ID: 16529836
[TBL] [Abstract][Full Text] [Related]
7. Retroviral vector performance in defined chromosomal Loci of modular packaging cell lines.
Gama-Norton L; Herrmann S; Schucht R; Coroadinha AS; Löw R; Alves PM; Bartholomae CC; Schmidt M; Baum C; Schambach A; Hauser H; Wirth D
Hum Gene Ther; 2010 Aug; 21(8):979-91. PubMed ID: 20222806
[TBL] [Abstract][Full Text] [Related]
8. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
Persons DA; Mehaffey MG; Kaleko M; Nienhuis AW; Vanin EF
Blood Cells Mol Dis; 1998 Jun; 24(2):167-82. PubMed ID: 9642098
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-art of the production of retroviral vectors.
Merten OW
J Gene Med; 2004 Feb; 6 Suppl 1():S105-24. PubMed ID: 14978755
[TBL] [Abstract][Full Text] [Related]
10. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
[TBL] [Abstract][Full Text] [Related]
11. Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration.
Bandeira VS; Tomás HA; Alici E; Carrondo MJ; Coroadinha AS
Hum Gene Ther Methods; 2017 Apr; 28(2):78-90. PubMed ID: 28301970
[TBL] [Abstract][Full Text] [Related]
12. Production of retroviral vectors: review.
Coroadinha AS; Gama-Norton L; Amaral AI; Hauser H; Alves PM; Cruz PE
Curr Gene Ther; 2010 Dec; 10(6):456-73. PubMed ID: 21054246
[TBL] [Abstract][Full Text] [Related]
13. Impact of retroviral vector components stoichiometry on packaging cell lines: effects on productivity and vector quality.
Carrondo MJ; Merten OW; Haury M; Alves PM; Coroadinha AS
Hum Gene Ther; 2008 Feb; 19(2):199-210. PubMed ID: 18092921
[TBL] [Abstract][Full Text] [Related]
14. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
15. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
Murauer EM; Gache Y; Gratz IK; Klausegger A; Muss W; Gruber C; Meneguzzi G; Hintner H; Bauer JW
J Invest Dermatol; 2011 Jan; 131(1):74-83. PubMed ID: 20720561
[TBL] [Abstract][Full Text] [Related]
16. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays.
Printz M; Reynolds J; Mento SJ; Jolly D; Kowal K; Sajjadi N
Gene Ther; 1995 Mar; 2(2):143-50. PubMed ID: 7719931
[TBL] [Abstract][Full Text] [Related]
17. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations.
Kaptein LC; Greijer AE; Valerio D; van Beusechem VW
Gene Ther; 1997 Feb; 4(2):172-6. PubMed ID: 9081708
[TBL] [Abstract][Full Text] [Related]
18. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease.
Stewart HJ; Fong-Wong L; Strickland I; Chipchase D; Kelleher M; Stevenson L; Thoree V; McCarthy J; Ralph GS; Mitrophanous KA; Radcliffe PA
Hum Gene Ther; 2011 Mar; 22(3):357-69. PubMed ID: 21070114
[TBL] [Abstract][Full Text] [Related]
19. Production of retroviral vectors for clinical use.
Cornetta K; Reeves L; Cross S
Methods Mol Biol; 2008; 433():17-32. PubMed ID: 18679615
[TBL] [Abstract][Full Text] [Related]
20. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience.
Reeves L; Smucker P; Cornetta K
Hum Gene Ther; 2000 Oct; 11(15):2093-103. PubMed ID: 11044911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
